MDT

89.42

+0.45%↑

VEEV

284.11

+0.3%↑

A

124.34

+2.53%↑

WBA

11.54

-0.09%↓

HQY

98.16

-1.3%↓

MDT

89.42

+0.45%↑

VEEV

284.11

+0.3%↑

A

124.34

+2.53%↑

WBA

11.54

-0.09%↓

HQY

98.16

-1.3%↓

MDT

89.42

+0.45%↑

VEEV

284.11

+0.3%↑

A

124.34

+2.53%↑

WBA

11.54

-0.09%↓

HQY

98.16

-1.3%↓

MDT

89.42

+0.45%↑

VEEV

284.11

+0.3%↑

A

124.34

+2.53%↑

WBA

11.54

-0.09%↓

HQY

98.16

-1.3%↓

MDT

89.42

+0.45%↑

VEEV

284.11

+0.3%↑

A

124.34

+2.53%↑

WBA

11.54

-0.09%↓

HQY

98.16

-1.3%↓

Search

Hutchison China MediTech Ltd ADR

Cerrado

SectorSalud

15.92 -1.79

Resumen

Variación precio

24h

Actual

Mínimo

15.56

Máximo

16.09

Métricas clave

By Trading Economics

Ingresos

6M

Ventas

162M

P/B

Media del Sector

77.1

39.564

Margen de beneficio

3.676

Empleados

1,811

EBITDA

-5M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+16.99% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

2.7B

Apertura anterior

17.71

Cierre anterior

15.92

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

Hutchison China MediTech Ltd ADR Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

9 jul 2025, 15:46 UTC

Principales Movimientos del Mercado

BitMine Shares Fall After Closing of $250 Million Private Placement

9 jul 2025, 23:44 UTC

Charlas de Mercado

Gold Edges Higher Amid U.S. Tariff Concerns -- Market Talk

9 jul 2025, 23:42 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

9 jul 2025, 23:42 UTC

Charlas de Mercado

Nikkei May Trade Rangebound as U.S. Tariff Uncertainty Continues -- Market Talk

9 jul 2025, 22:59 UTC

Charlas de Mercado

Reliance Worldwide's Costs at Risk From Copper Tariffs -- Market Talk

9 jul 2025, 22:59 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

9 jul 2025, 20:50 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Health Care Roundup: Market Talk

9 jul 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

9 jul 2025, 20:26 UTC

Ganancias

Nvidia Is the Most Valuable Company Ever. Why $5 Trillion Could Be Next. -- Barrons.com

9 jul 2025, 19:18 UTC

Charlas de Mercado

Oil Futures End Little Changed After Big U.S. Crude Stock Build -- Market Talk

9 jul 2025, 19:03 UTC

Charlas de Mercado

U.S. Natural Gas Posts Back-to-Back Losses -- Market Talk

9 jul 2025, 18:31 UTC

Charlas de Mercado

Some Fed Officials Supported Considering July Cut -- Market Talk

9 jul 2025, 17:07 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Honeywell's Streamlining Efforts Clear Path for Stock to Catch Up -- Market Talk

9 jul 2025, 16:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk -2-

9 jul 2025, 16:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

9 jul 2025, 16:20 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Health Care Roundup: Market Talk

9 jul 2025, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

9 jul 2025, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

9 jul 2025, 16:14 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

9 jul 2025, 16:14 UTC

Charlas de Mercado

Rents in Canada Soften For Ninth-Straight Month -- Market Talk

9 jul 2025, 16:14 UTC

Adquisiciones, fusiones, absorciones

Apple Has Dropped the Ball on AI. Buying Perplexity Could Help It Catch Up, Say Analysts. -- Barrons.com

9 jul 2025, 16:12 UTC

Charlas de Mercado

Gold Futures Broadly Flat in Largely Directionless Trade -- Market Talk

9 jul 2025, 16:08 UTC

Charlas de Mercado

Oil Ticks Higher Amid Large U.S. Crude Build, Red Sea Tensions, Tariff Uncertainty -- Market Talk

9 jul 2025, 15:31 UTC

Principales Movimientos del Mercado

BitMine Shares Fall After Closing of $250M Private Placement

9 jul 2025, 15:31 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

With Competing Bids Unlikely, Merck's Path to Acquiring Verona Looks Smooth -- Market Talk

9 jul 2025, 15:27 UTC

Charlas de Mercado

Copper Rally Expected to Fade Amid Tepid Global Demand -- Market Talk

9 jul 2025, 14:36 UTC

Adquisiciones, fusiones, absorciones

Merck to Buy Verona Pharma in $10 Billion Deal -- 2nd Update

9 jul 2025, 14:31 UTC

Adquisiciones, fusiones, absorciones

Meta Has Surged on the Back of AI Software. Why Hardware Is the Next Play. -- Barrons.com

9 jul 2025, 14:26 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

9 jul 2025, 14:26 UTC

Charlas de Mercado

Aug 1 Tariffs Will Boost Average Rate Near 15%, JPMorgan Estimates -- Market Talk

Comparación entre iguales

Cambio de precio

Hutchison China MediTech Ltd ADR Esperado

Precio Objetivo

By TipRanks

16.99% repunte

Estimación a 12 meses

Media 19.07 USD  16.99%

Máximo 27 USD

Mínimo 14.7 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Hutchison China MediTech Ltd ADR Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

3 ratings

1

Comprar

2

Mantener

0

Vender

Puntuación técnica

By Trading Central

14.24 / 14.78Soporte y Resistencia

Corto Plazo

Strong Bearish Evidence

Medio plazo

Weak Bearish Evidence

Largo Plazo

Weak Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.